查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1942760

2026年全球藥物洗脫支架市場報告

Drug Eluting Stent Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，藥物釋放型支架市場經歷了顯著成長，預計將從2025年的82.6億美元成長到2026年的89.4億美元，複合年成長率為8.2%。過去幾年的成長可歸因於冠狀動脈疾病盛行率的上升、經經皮冠狀動脈介入治療（PCI）手術量的增加、文明病相關心血管疾病發病率的上升、心臟導管檢查室的擴建以及與裸金屬支架相比臨床療效的改善。

預計未來幾年藥物釋放型支架市場規模將強勁成長，2030年將達到117億美元，複合年成長率（CAGR）為6.9%。預測期內的成長要素包括人口老化、對微創心臟手術需求的成長、對先進支架技術的認知度提高、專科心臟病診所的擴張以及心血管護理醫療費用支出的增加。預測期內的主要趨勢包括可生物分解聚合物支架的日益普及、對無聚合物藥物釋放型支架的偏好不斷增強、其在複雜冠狀動脈介入治療中的應用範圍擴大、向長期預防血管再阻塞的轉變以及對改進的控制釋放的需求不斷成長。

冠狀動脈疾病（CHD）日益嚴重的負擔預計將推動藥物釋放型支架市場的未來成長。冠狀動脈疾病（CHD）是指冠狀動脈因斑塊堆積而變窄或阻塞的疾病，可能導致心肌梗塞和胸痛等嚴重併發症。久坐的生活方式、不良的飲食習慣、人口老化以及人們對該疾病的認知提高，都導致冠狀動脈疾病的發生率不斷上升。藥物釋放型支架（DES）透過有效擴張狹窄或阻塞的冠狀動脈並釋放藥物來防止動脈再次血管再阻塞（血管再阻塞），有助於治療心臟疾病。例如，根據美國政府機構國家生物技術資訊中心（NCBI）的數據，截至2025年8月，預計2025年至2050年間心血管疾病將顯著增加，盛行率將上升90.0%，粗死亡率將上升73.4%，粗傷殘調整壽命年（DALYs）將上升54.7%。這將導致心血管疾病死亡人數增加，預計到2050年將達到3560萬，而2025年為2050萬。心臟疾病負擔的加重預計將推動藥物釋放型支架市場的成長。

藥物釋放型支架市場的主要企業正致力於開發創新產品，例如低輪廓、高柔軟性支架，以提高其在複雜冠狀動脈解剖結構中的輸送性能，並改善患者預後。低輪廓、高柔軟性支架是藥物釋放型支架，其通過血管的阻力更小，柔軟性更高，使其能夠更輕鬆地穿過狹窄、迂曲和鈣化的冠狀動脈，同時保持有效的藥物輸送，從而預防血管再阻塞。例如，2024年5月，總部位於美國的全球醫療保健公司雅培（Abbott Laboratories）在印度推出了XIENCE Sierra依Everolimus洗脫冠狀動脈支架系統。 XIENCE Sierra採用新型支架設計，與同類產品相比，具有一流的輸送性能和顯著降低的通過阻力。它還具有更薄的球囊和最佳化的MULTI-LINK結構，從而提高了柔軟性，同時其高縱向強度確保了支架的穩定性和抗變形能力。此外，寬廣的擴張範圍使得即使病變部位的血管直徑發生變化，也能進行精確治療，從而使介入性心臟病專家能夠更精確、更安全地處理複雜、鈣化或難以觸及的病變。

目錄

第1章執行摘要

第2章 市場特徵

  • 市場定義和範圍
  • 市場區隔
  • 主要產品和服務概述
  • 全球藥物洗脫支架市場：吸引力評分及分析
  • 成長潛力分析、競爭評估、策略契合度評估、風險狀況評估

第3章 市場供應鏈分析

  • 供應鏈與生態系概述
  • 主要原料、資源和供應商清單
  • 主要經銷商和通路合作夥伴名單
  • 主要最終用戶列表

第4章 全球市場趨勢與策略

  • 關鍵技術和未來趨勢
    • 生物技術、基因組學和精準醫學
    • 工業4.0和智慧製造
    • 數位化、雲端運算、巨量資料、網路安全
    • 人工智慧（AI）和自主人工智慧
    • 永續性、氣候技術和循環經濟
  • 主要趨勢
    • 擴大可生物分解聚合物支架的應用
    • 消費者越來越傾向選擇不含聚合物的塗藥支架
    • 在複雜冠狀動脈介入治療的應用日益增多
    • 過渡到長期預防血管再阻塞
    • 改良型控釋控制釋放的需求日益成長

第5章 終端用戶產業市場分析

  • 醫院
  • 專科診所
  • 心臟導管檢查室
  • 門診心臟護理中心
  • 三級心臟病中心

第6章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅的影響、關稅戰和貿易保護主義對供應鏈的影響，以及新冠疫情對市場的影響

第7章 全球策略分析架構、目前市場規模、市場對比及成長率分析

  • 全球藥物洗脫支架市場：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 全球藥物洗脫支架市場規模、比較及成長率分析
  • 全球藥物洗脫支架市場表現：規模與成長，2020-2025年
  • 全球藥物洗脫支架市場預測：規模與成長，2025-2030年，2035年預測

第8章 全球潛在市場規模（TAM）

第9章 市場細分

  • 依產品
  • 基於聚合物的，不含聚合物的
  • 藥物
  • Sirolimus、紫杉醇、佐他莫司、Everolimus、比奧利莫司和其他藥物
  • 由鷹架
  • 鈷鉻合金、鉑鉻合金、鎳鈦諾、可生物分解材料及其他支架
  • 透過使用
  • 冠狀動脈疾病、周邊血管疾病
  • 最終用戶
  • 醫院、專科診所
  • 按類型細分：聚合物基
  • 耐久型聚合物藥物釋放型支架，可生物分解型聚合物藥物釋放型支架
  • 按類型細分：無聚合物
  • 藥物塗層裸金屬支架和其他不含聚合物的藥物釋放型支架

第10章 區域與國家分析

  • 全球藥物洗脫支架市場：依地區、績效及預測分類，2020-2025年、2025-2030年預測、2035年預測
  • 全球藥物洗脫支架市場：依國家、表現及預測分類，2020-2025年、2025-2030年預測、2035年預測

第11章 亞太市場

第12章：中國市場

第13章 印度市場

第14章 日本市場

第15章：澳洲市場

第16章 印尼市場

第17章 韓國市場

第18章 台灣市場

第19章 東南亞市場

第20章：西歐市場

第21章英國市場

第22章 德國市場

第23章：法國市場

第24章：義大利市場

第25章：西班牙市場

第26章 東歐市場

第27章：俄羅斯市場

第28章 北美市場

第29章：美國市場

第30章：加拿大市場

第31章 南美洲市場

第32章：巴西市場

第33章 中東市場

第34章：非洲市場

第35章 市場監理與投資環境

第36章：競爭格局與公司概況

  • 藥物洗脫支架市場：競爭格局及市場佔有率（2024年）
  • 藥物洗脫支架市場：公司估值矩陣
  • 藥物洗脫支架市場：公司概況
    • Abbott Laboratories
    • Boston Scientific Corporation
    • Medtronic plc
    • Terumo Corporation
    • BIOTRONIK SE & Co KG

第37章：其他領先和創新企業

  • Biosensors International Group Ltd, MicroPort Scientific Corporation, Lepu Medical Technology Beijing Co Ltd, Meril Life Sciences Pvt Ltd, Sahajanand Medical Technologies Pvt Ltd, Alvimedica Medical Technologies, Balton Sp z oo, Cordis（Cardinal Health）DES Manufacturing, Shandong JW Medical Systems Ltd, Sino Medical Sciences Technology Inc, STENTYS SA, Relisys Medical Devices Ltd, Translumina GmbH, Eurocor GmbH, Elixir Medical Corporation

第38章 全球市場競爭基準分析與儀錶板

第39章 重大併購

第40章：高潛力市場國家、細分市場與策略

  • 2030年藥物洗脫支架市場：提供新機會的國家
  • 2030年藥物洗脫支架市場：充滿新機會的細分市場
  • 2030年藥物洗脫支架市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第41章附錄

簡介目錄
Product Code: ME3MDESL01_G26Q1

A drug-eluting stent (DES) is a medical device employed in the treatment of coronary artery disease (CAD). It constitutes a small, mesh-like tube typically constructed from metal, which is inserted into narrowed or blocked coronary arteries during a procedure known as percutaneous coronary intervention (PCI) or angioplasty.

The primary product types of drug-eluting stents include polymer-based and polymer-free varieties. Polymer-based drug-eluting stents (DES) are stents coated with a thin polymer layer that encapsulates the drug(s) intended for delivery to the arterial wall. These drugs may include sirolimus, paclitaxel, zotarolimus, everolimus, biolimus, among others, with scaffolds such as cobalt-chromium, platinum-chromium, nitinol, biodegradable materials, and others. They find application in coronary diseases and peripheral vascular disease and are utilized by end-users such as hospitals and specialty clinics.

Tariffs are impacting the drug eluting stent market by increasing costs of imported metal scaffolds, drug compounds, and precision manufacturing equipment used in stent production. These effects are most evident across polymer-based and biodegradable scaffold segments, particularly in regions dependent on cross-border medical device supply chains such as Asia-Pacific and Europe. Higher tariffs have moderately increased procurement costs for hospitals and specialty clinics. At the same time, tariffs are encouraging local manufacturing, supplier diversification, and regional production investments, supporting long-term supply chain resilience.

The drug eluting stent market research report is one of a series of new reports from The Business Research Company that provides drug eluting stent market statistics, including drug eluting stent industry global market size, regional shares, competitors with a drug eluting stent market share, detailed drug eluting stent market segments, market trends and opportunities, and any further data you may need to thrive in the drug eluting stent industry. This drug eluting stent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drug eluting stent market size has grown strongly in recent years. It will grow from $8.26 billion in 2025 to $8.94 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increasing prevalence of coronary artery disease, growth in percutaneous coronary intervention procedures, rising incidence of lifestyle-related cardiovascular conditions, expansion of cardiac catheterization labs, improved clinical outcomes compared to bare-metal stents.

The drug eluting stent market size is expected to see strong growth in the next few years. It will grow to $11.7 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to growing aging population, increasing demand for minimally invasive cardiac treatments, rising awareness of advanced stent technologies, expansion of specialty cardiac clinics, increasing healthcare expenditure on cardiovascular care. Major trends in the forecast period include rising adoption of biodegradable polymer stents, growing preference for polymer-free drug-eluting stents, increasing use in complex coronary interventions, shift toward long-term restenosis prevention, rising demand for improved drug release control.

The rising burden of coronary heart disease is expected to propel the growth of the drug-eluting stent market going forward. Coronary heart disease (CHD) is a condition where the coronary arteries become narrowed or blocked due to plaque buildup, potentially leading to severe complications such as a heart attack or chest pain. Coronary heart disease is increasing due to sedentary lifestyles, poor diets, aging populations, and heightened awareness. Drug-eluting stents (DES) benefit coronary heart disease by effectively opening narrowed or blocked coronary arteries and releasing medication that helps prevent re-narrowing (restenosis) of the artery. For example, in August 2025, according to the National Center for Biotechnology Information, a US-based government agency, between 2025 and 2050, cardiovascular disease is projected to rise significantly, with prevalence increasing by 90.0%, crude mortality by 73.4%, and crude DALYs by 54.7%, resulting in an estimated 35.6 million cardiovascular deaths in 2050, up from 20.5 million in 2025. The rising burden of coronary heart disease is expected to propel the growth of the drug-eluting stench market.

Major companies operating in the drug-eluting stent market are focusing on developing innovative products, such as low-profile, high-flexibility stents, to improve deliverability in complex coronary anatomies and enhance patient outcomes. A low-profile, high-flexibility stent is a drug-eluting stent designed with a reduced crossing profile and enhanced flexibility, enabling it to navigate narrow, tortuous, or calcified coronary arteries more easily while maintaining effective drug delivery to prevent restenosis. For example, in May 2024, Abbott Laboratories, a US-based global healthcare company, launched the XIENCE Sierra Everolimus Eluting Coronary Stent System in India. The XIENCE Sierra features a novel stent design that provides best-in-class deliverability with significantly reduced crossing force compared to competitors. It also includes a thinner balloon and an optimized MULTI LINK structure to enhance flexibility, while its high longitudinal strength ensures scaffold stability and resistance to deformation. Additionally, it offers a wide expansion range, allowing precise treatment even when vessel diameters vary along the lesion, enabling interventional cardiologists to address complex, calcified, or difficult-to-reach lesions with improved precision and safety.

In October 2023, Cordis acquired MedAlliance for an undisclosed sum. This acquisition is aimed at furthering Cordis' tradition of cardiovascular innovation and expanding its product portfolio in the coronary and peripheral vascular markets. MedAlliance is a Switzerland-based medical device manufacturer and distributor specializing in drug-eluting stents.

Major companies operating in the drug eluting stent market are Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Terumo Corporation, BIOTRONIK SE & Co KG, Biosensors International Group Ltd, MicroPort Scientific Corporation, Lepu Medical Technology Beijing Co Ltd, Meril Life Sciences Pvt Ltd, Sahajanand Medical Technologies Pvt Ltd, Alvimedica Medical Technologies, Balton Sp z oo, Cordis (Cardinal Health) DES Manufacturing, Shandong JW Medical Systems Ltd, Sino Medical Sciences Technology Inc, STENTYS SA, Relisys Medical Devices Ltd, Translumina GmbH, Eurocor GmbH, Elixir Medical Corporation

North America was the largest region in the drug-eluting stent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the drug eluting stent market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The drug eluting stent market consists of revenues earned by entities by providing services such as pre-procedural assessment, procedural intervention, intraoperative monitoring, post-procedural care, and patient education. The market value includes the value of related goods sold by the service provider or included within the service offering. The drug eluting stenting market also includes sales of products including guide wires, angioplasty equipment, intravascular imaging systems, hemostasis devices, and diagnostic tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Drug Eluting Stent Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses drug eluting stent market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for drug eluting stent ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug eluting stent market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Product: Polymer-Based; Polymer-Free
  • 2) By Drug: Sirolimus; Paclitaxel; Zotarolimus; Everolimus; Biolimus; Other Drugs
  • 3) By Scaffold: Cobalt-Chromium; Platinum-Chromium; Nitinol; Biodegradable; Other Scaffolds
  • 4) By Application: Coronary Diseases; Peripheral Vascular Diseases
  • 5) By End-User: Hospitals; Specialty Clinics
  • Subsegments:
  • 1) By Polymer-Based: Durable Polymer Drug-Eluting Stents; Biodegradable Polymer Drug-Eluting Stents
  • 2) By Polymer-Free: Bare-Metal Stents With Drug Coating; Other Polymer-Free Drug-Eluting Stents
  • Companies Mentioned: Abbott Laboratories; Boston Scientific Corporation; Medtronic plc; Terumo Corporation; BIOTRONIK SE & Co KG; Biosensors International Group Ltd; MicroPort Scientific Corporation; Lepu Medical Technology Beijing Co Ltd; Meril Life Sciences Pvt Ltd; Sahajanand Medical Technologies Pvt Ltd; Alvimedica Medical Technologies; Balton Sp z oo; Cordis (Cardinal Health) DES Manufacturing; Shandong JW Medical Systems Ltd; Sino Medical Sciences Technology Inc; STENTYS SA; Relisys Medical Devices Ltd; Translumina GmbH; Eurocor GmbH; Elixir Medical Corporation
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Drug Eluting Stent Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Drug Eluting Stent Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Drug Eluting Stent Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Drug Eluting Stent Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Industry 4.0 & Intelligent Manufacturing
    • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.4 Artificial Intelligence & Autonomous Intelligence
    • 4.1.5 Sustainability, Climate Tech & Circular Economy
  • 4.2. Major Trends
    • 4.2.1 Rising Adoption Of Biodegradable Polymer Stents
    • 4.2.2 Growing Preference For Polymer-Free Drug-Eluting Stents
    • 4.2.3 Increasing Use In Complex Coronary Interventions
    • 4.2.4 Shift Toward Long-Term Restenosis Prevention
    • 4.2.5 Rising Demand For Improved Drug Release Control

5. Drug Eluting Stent Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Specialty Clinics
  • 5.3 Cardiac Catheterization Laboratories
  • 5.4 Ambulatory Cardiac Care Centers
  • 5.5 Tertiary Care Cardiology Centers

6. Drug Eluting Stent Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Drug Eluting Stent Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Drug Eluting Stent PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Drug Eluting Stent Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Drug Eluting Stent Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Drug Eluting Stent Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Drug Eluting Stent Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Drug Eluting Stent Market Segmentation

  • 9.1. Global Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Polymer-Based, Polymer-Free
  • 9.2. Global Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, Other Drugs
  • 9.3. Global Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cobalt-Chromium, Platinum-Chromium, Nitinol, Biodegradable, Other Scaffolds
  • 9.4. Global Drug Eluting Stent Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Coronary Diseases, Peripheral Vascular Diseases
  • 9.5. Global Drug Eluting Stent Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals, Specialty Clinic
  • 9.6. Global Drug Eluting Stent Market, Sub-Segmentation Of Polymer-Based, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Durable Polymer Drug-Eluting Stents, Biodegradable Polymer Drug-Eluting Stents
  • 9.7. Global Drug Eluting Stent Market, Sub-Segmentation Of Polymer-Free, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Bare-Metal Stents With Drug Coating, Other Polymer-Free Drug-Eluting Stents

10. Drug Eluting Stent Market Regional And Country Analysis

  • 10.1. Global Drug Eluting Stent Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Drug Eluting Stent Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Drug Eluting Stent Market

  • 11.1. Asia-Pacific Drug Eluting Stent Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Drug Eluting Stent Market

  • 12.1. China Drug Eluting Stent Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Drug Eluting Stent Market

  • 13.1. India Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Drug Eluting Stent Market

  • 14.1. Japan Drug Eluting Stent Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Drug Eluting Stent Market

  • 15.1. Australia Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Drug Eluting Stent Market

  • 16.1. Indonesia Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Drug Eluting Stent Market

  • 17.1. South Korea Drug Eluting Stent Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Drug Eluting Stent Market

  • 18.1. Taiwan Drug Eluting Stent Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Drug Eluting Stent Market

  • 19.1. South East Asia Drug Eluting Stent Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Drug Eluting Stent Market

  • 20.1. Western Europe Drug Eluting Stent Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Drug Eluting Stent Market

  • 21.1. UK Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Drug Eluting Stent Market

  • 22.1. Germany Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Drug Eluting Stent Market

  • 23.1. France Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Drug Eluting Stent Market

  • 24.1. Italy Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Drug Eluting Stent Market

  • 25.1. Spain Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Drug Eluting Stent Market

  • 26.1. Eastern Europe Drug Eluting Stent Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Drug Eluting Stent Market

  • 27.1. Russia Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Drug Eluting Stent Market

  • 28.1. North America Drug Eluting Stent Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Drug Eluting Stent Market

  • 29.1. USA Drug Eluting Stent Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Drug Eluting Stent Market

  • 30.1. Canada Drug Eluting Stent Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Drug Eluting Stent Market

  • 31.1. South America Drug Eluting Stent Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Drug Eluting Stent Market

  • 32.1. Brazil Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Drug Eluting Stent Market

  • 33.1. Middle East Drug Eluting Stent Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Drug Eluting Stent Market

  • 34.1. Africa Drug Eluting Stent Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Drug Eluting Stent Market Regulatory and Investment Landscape

36. Drug Eluting Stent Market Competitive Landscape And Company Profiles

  • 36.1. Drug Eluting Stent Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Drug Eluting Stent Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Drug Eluting Stent Market Company Profiles
    • 36.3.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Terumo Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. BIOTRONIK SE & Co KG Overview, Products and Services, Strategy and Financial Analysis

37. Drug Eluting Stent Market Other Major And Innovative Companies

  • Biosensors International Group Ltd, MicroPort Scientific Corporation, Lepu Medical Technology Beijing Co Ltd, Meril Life Sciences Pvt Ltd, Sahajanand Medical Technologies Pvt Ltd, Alvimedica Medical Technologies, Balton Sp z oo, Cordis (Cardinal Health) DES Manufacturing, Shandong JW Medical Systems Ltd, Sino Medical Sciences Technology Inc, STENTYS SA, Relisys Medical Devices Ltd, Translumina GmbH, Eurocor GmbH, Elixir Medical Corporation

38. Global Drug Eluting Stent Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Drug Eluting Stent Market

40. Drug Eluting Stent Market High Potential Countries, Segments and Strategies

  • 40.1 Drug Eluting Stent Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Drug Eluting Stent Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Drug Eluting Stent Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer